The 20 Best Triple-Negative Breast Cancer Doctors Near Me

Eric Winer is an Oncologist and a Hematologist Oncology provider in New Haven, Connecticut. Dr. Winer is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, HER-2 Positive Breast Cancer, and Breast Cancer in Men.

Dr. O'Shaughnessy is a Medical Oncologist that focuses on breast cancer prevention and treatment. She founded The School of Breast Oncology, a program providing a curriculum-based program focused exclusively on breast cancer clinical management. Dr. O'Shaughnessy attended medical school at Yale University School of Medicine in New Haven, CT. She then completed her Internal Medicine residency at Massachusetts General Hospital in Boston, MA and a Medical Oncology fellowship at National Cancer Institute in Bethesda, MD. She is co-chair of Breast Cancer Research, chair of Breast Cancer Prevention Research at Baylor Charles A. Sammons Cancer Center and a member of the Scientific Advisory Board for US Oncology Research Network. Dr. O'shaughnessy is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, HER2 Negative Breast Cancer, and Tissue Biopsy.

Elizabeth Mittendorf is a Surgical Oncologist in Boston, Massachusetts. Dr. Mittendorf is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer, and Lymphadenectomy.

Dr. Alastair Thompson is a surgical oncologist specializing in breast cancer. He is the Professor and Chief of the Division of Surgical Oncology, Section of Breast Surgery at Baylor College of Medicine, where he holds the Olga Keith Wiess Chair of Surgery. He also serves as Co-Director of the Lester and Sue Smith Breast Center and is Co-Associate Director for Clinical Research at the Dan L Duncan Comprehensive Cancer Center.Dr. Thomspon’s clinical interests include: ductal carcinoma in situ (DCIS); nipple and skin sparing mastectomy; breast conservation surgery; and sentinel lymph node biopsy. His research interests include: multidisciplinary patient care alongside “bench to bedside” studies; and innovative clinical trials in cancer. He initiated and led a successful breast cancer laboratory program; provided leadership for a cancer center in the United Kingdom; chaired the UK national breast cancer trials portfolio of 120 studies; and engaged in a range of pivotal roles in key drug, radiation therapy and surgical trials involving the UK, Europe, United States and Australia.Dr. Thompson also has preclinical and practical experience in the design, implementation, monitoring and reporting of early- to late-phase drug and medical device trials. Dr. Thompson received his MBChB in Medicine Surgery and medical degree in Molecular Biology from the University of Edinburgh in Edinburgh, Scotland. He completed his residency in general surgery at the Royal Infirmary of Edinburgh and a Research Fellowship at the Imperial Cancer Research Fund in Edinburgh.Dr. Thompson has co-chaired the Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for low-risk DCIS; and the National Cancer Institute (NCI)-Breast Cancer Steering Committee proposed “no surgery” clinical trial planning committee. He is a member of the NCI BOLD taskforce and has held leadership positions in the Translational Breast Cancer Research Consortium and SWOG Cancer Research Network.Dr. Thompson is also a member of the American Society of Clinical Oncology, Association of Breast Surgery, British Association of Surgical Oncology, British Breast Group, American Society of Breast Surgeons, American Association for Cancer Research, Moynihan Chirurgical Club, and the Society of Surgical Oncology. Dr. Thompson is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, Mastectomy, and Tissue Biopsy.

Dr. Tolaney is Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School.  She is a breast medical oncologist whose research focuses on the development of novel therapies in the treatment of breast cancer.  She has been instrumental in developing several treatment approaches for breast cancer, including approaches focused on tailoring therapy for early stage HER2+ disease, use of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy.She is a member of the National Cancer Institute Breast Cancer Steering Committee and is Vice Chair for Late-Stage Development in Breast Cancer in the Alliance for Clinical Trials in Oncology. Her research has been funded by the Breast Cancer Research Foundation and Susan G. Komen. She currently chairs multiple phase 3 trials in breast cancer and serves on several steering committees for practice-changing trials.  Her work has been published in journals such as the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology, and others. She received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007. In 2008, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital. Dr. Tolaney is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. Her top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer, and Triple-Negative Breast Cancer.

My clinical practice if focused on the care of patients with breast cancer, particularly those diagnosed at a younger age and those with recurrence in the central nervous system. I am committed to the care of patients with breast cancer brain metastases, and I am honored to serve as the Medical Director of the Brain and Spine Metastases Program in the Duke Cancer Center. In this role, our multidisciplinary team provides well-coordinated care for patients with breast cancer and other solid tumor types that have metastasized to the central nervous system. In addition, I enjoy helping young women diagnosed with breast cancer navigate their treatment decisions to ensure both excellent medical care and attention to individual challenges, such as future fertility, sequelae of treatment on longer-term health, and impact on current and future relationships. When not working, I enjoy running, reading, and traveling with my family. Dr. Anders is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Brain Tumor, Triple-Negative Breast Cancer, and Metastatic Brain Tumor.

Dr. Lynce received her medical degree from the Universidade Nova de Lisboa, Portugal in 2004. She completed her residency in Internal Medicine and fellowship in Hematology and Medical Oncology at MedStar Washington Hospital Center/MedStar Georgetown University Hospital in Washington, DC. She was faculty at MedStar Georgetown University Hospital from 2015 to 2020 where she served as the institutional PI for Alliance and the co-PI for the National Capital Area (NCA) Minority/Underserved NCORP. In 2020, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital, where she is a medical oncologist and clinical investigator in the Breast Oncology Center. Her research focuses on inflammatory breast cancer, triple-negative breast cancer, BRCA-associated breast cancers and novel therapies in the treatment of breast cancer. Dr. Lynce is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. Her top areas of expertise are Inflammatory Breast Cancer, Breast Cancer, Triple-Negative Breast Cancer, Angiosarcoma, and Salpingo-Oophorectomy.

Adam M. Brufsky, MD, PhD, FACP, is professor of medicine at the University of Pittsburgh School of Medicine and also serves as the associate division chief for the Division of Hematology/Oncology at the University of Pittsburgh School of Medicine's Department of Medicine. Dr. Brufsky is the medical director of the Magee-Women's Cancer Program, part of the UPMC Hillman Cancer Center, and UPMC Hillman Cancer Center; associate director for clinical investigations at UPMC Hillman Cancer Center; and codirector of the Comprehensive Breast Cancer Center.Dr. Brufsky is board-certified in internal medicine and medical oncology. He earned a medical and doctor of philosophy degrees from the University of Connecticut School of Medicine in Farmington, Conn.; completed a residency at Brigham and Women's Hospital, Harvard Medical School, and a fellowship at Dana-Farber Cancer Institute.Dr. Brufsky is a member of professional organizations, such as American Medical Association, Massachusetts Medical Society, American College of Physicians, American Society of Clinical Oncology, American Association for Cancer Research, Allegheny County Medical Society, Pennsylvania Medical Society, and Pennsylvania Oncologic Society. An active researcher, Dr. Brufsky has numerous abstracts and research articles in leading journals, and is principal investigator on a number of research grants funded by the National Institutes of Health, Susan G. Komen Foundation, and US Army - Breast Cancer Research Program. Dr. Brufsky is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, Breast Cancer in Men, and Gastrostomy.

Dr. Antonio Wolff is internationally recognized for his work on breast cancer biomarkers, including HER2. As a practicing oncologist and clinical translational researcher, his research has been pivotal to improve the quality of breast cancer biomarker testing in breast cancer, including HER2 and estrogen receptor testing. Among his leadership accomplishments is ensuring that sophisticated laboratory findings are translated into improved clinical care in breast cancer. He is a Fellow of the American Society of Clinical Oncology (ASCO), a Komen Scholar and a Breast Cancer Research Foundation investigator. He has served as associate editor for Journal of Clinical Oncology, and serves on the National Comprehensive Cancer Network (NCCN) Guideline Steering Committee. He is a leader of the Translational Breast Cancer Research Consortium (TBCRC), and one of the principal investigators of the Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (EVOLVE) in Metastatic Breast Cancer, which was one of the three disease groups recently awarded by ARPA-H to conduct innovative trials using Advanced Analysis for Precision Cancer Therapy (ADAPT). After many years of service as Breast Committee Chair in the ECOG-ACRIN Clinical Trial Network of the National Cancer Institute (NCI), he was elected in 2024 as Co-Chair of the NCI Breast Cancer Steering Committee and appointed to the international steering committee of the Oxford Overview Collaborative, which are positions aimed at advancing clinical trials in breast cancer. At Johns Hopkins, he is an elected member of the Miller Coulson Academy of Clinical Excellence and was honored during the 125th Anniversary Living the Hopkins Mission celebrations of the JHU School of Medicine. Dr. Wolff is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. His top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Triple-Negative Breast Cancer, and Inflammatory Breast Cancer.

Bridgette Collins is an Endocrinologist in New Orleans, Louisiana. Dr. Collins is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. Her top areas of expertise are Triple-Negative Breast Cancer, Breast Cancer, Paget Disease of the Breast, and Inflammatory Breast Cancer.

Lajos Pusztai is an Oncologist in New Haven, Connecticut. Dr. Pusztai is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. His top areas of expertise are Triple-Negative Breast Cancer, Breast Cancer, Inflammatory Breast Cancer, HER2 Negative Breast Cancer, and Tissue Biopsy.

Sherene Loi practices in Parkville, Australia. Ms. Loi is rated as an Elite expert by MediFind in the treatment of Triple-Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, HER-2 Positive Breast Cancer, and Diarrhea.

Hope Rugo is an Oncologist in San Francisco, California. Dr. Rugo is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Agranulocytosis, Bone Marrow Aspiration, and Hormone Replacement Therapy (HRT).

Giuseppe Curigliano practices in Milan, Italy. Mr. Curigliano is rated as an Elite expert by MediFind in the treatment of Triple-Negative Breast Cancer. His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, HER-2 Positive Breast Cancer, Tissue Biopsy, and Mastectomy.

Sibylle Loibl practices in Neu Isenburg, Germany. Ms. Loibl is rated as an Elite expert by MediFind in the treatment of Triple-Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Breast Cancer in Men, Agranulocytosis, and Mastectomy.

Michael Untch practices in Bonn, Germany. Mr. Untch is rated as an Elite expert by MediFind in the treatment of Triple-Negative Breast Cancer. His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, HER2 Negative Breast Cancer, Mastectomy, and Salpingo-Oophorectomy.

Andreas Schneeweiss practices in Heidelberg, Germany. Mr. Schneeweiss is rated as an Elite expert by MediFind in the treatment of Triple-Negative Breast Cancer. His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, HER2 Negative Breast Cancer, Ovarian Cancer, and Mastectomy.

Roberto Salgado practices in Antwerpen, Belgium. Mr. Salgado is rated as an Elite expert by MediFind in the treatment of Triple-Negative Breast Cancer. His top areas of expertise are Triple-Negative Breast Cancer, Breast Cancer, HER-2 Positive Breast Cancer, Squamous Cell Lung Carcinoma, and Mastectomy.

Aditya Bardia is an Oncologist in Boston, Massachusetts. Dr. Bardia is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Agranulocytosis, Inflammatory Breast Cancer, and Tissue Biopsy.

Nadia Harbeck practices in Koeln, Germany. Ms. Harbeck is rated as an Elite expert by MediFind in the treatment of Triple-Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Agranulocytosis, HER-2 Positive Breast Cancer, and Mastectomy.